Study of Apatinib in Metastatic Esophageal Cancer
The purpose of this study is to assess the efficacy and safety of apatinib in Metastatic Esophageal Cancer.
Esophageal Cancer
DRUG: Apatinib|DRUG: Apatinib
Progression free survival, An expected average of 12 weeks
Eligible patients will receive apatinib treatment until disease progression or intolerable toxicity or patients withdrawal of consent after the failure of chemotherapy or radiotherapy.